Loading stock data…
ALXO
$1.88+0.19 (+11.24%)
Market ClosedLast close May 4
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ALX Oncology Holdings Inc. in the Healthcare sector is trading at $1.88. The stock is currently 29% below its 52-week high of $2.66, remaining 24.5% above its 200-day moving average. Technical signals show neutral RSI of 64 and bullish MACD crossover, explaining why ALXO maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 64) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.88
Potential Upside
5%
Whystock Fair Value$1.97
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$224.72M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.50
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-391.42%
Volume
Today's trading volume
705,244
Recent News
Favourable Signals For ALX Oncology Holdings: Numerous Insiders Acquired Stock
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?
BIAF is sharpening its focus on CyPath Lung, streamlining unprofitable services and pushing validation studies as it expands its lung-disease pipeline.
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA
Aldeyra Therapeutics stock plunges 71% after the FDA issues a third CRL for the resubmitted reproxalap NDA for the treatment of dry eye disease.
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastatic CRC show rising response rates and strong disease control.
IBRX Stock Jumps on Progress in NK Cell Therapy Production
ImmunityBio stock gains more than 7% after completing two programs, showing scalable production of M-ceNK NK cells and early safety data in solid tumor patients.